Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 25:2018:7045245.
doi: 10.1155/2018/7045245. eCollection 2018.

Functionally Improved Mesenchymal Stem Cells to Better Treat Myocardial Infarction

Zhi Chen  1 , Long Chen  2 , Chunyu Zeng  1 , Wei Eric Wang  1
Affiliations
Review

Functionally Improved Mesenchymal Stem Cells to Better Treat Myocardial Infarction

Zhi Chen et al. Stem Cells Int. .

Abstract

Myocardial infarction (MI) is one of the leading causes of death worldwide. Mesenchymal stem cell (MSC) transplantation is considered a promising approach and has made significant progress in preclinical studies and clinical trials for treating MI. However, hurdles including poor survival, retention, homing, and differentiation capacity largely limit the therapeutic effect of transplanted MSCs. Many strategies such as preconditioning, genetic modification, cotransplantation with bioactive factors, and tissue engineering were developed to improve the survival and function of MSCs. On the other hand, optimizing the hostile transplantation microenvironment of the host myocardium is also of importance. Here, we review the modifications of MSCs as well as the host myocardium to improve the efficacy of MSC-based therapy against MI.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The procedures of MSC-based therapy, including donor selection, cell expansion, dosage, injection routes, homing, and target tissue modification. MSCs: mesenchymal stem cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. doi: 10.1016/S0140-6736(14)61682-2. - DOI - PMC - PubMed
    1. Samsonraj R. M., Raghunath M., Nurcombe V., Hui J. H., van Wijnen A. J., Cool S. M. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Translational Medicine. 2017;6(12):2173–2185. doi: 10.1002/sctm.17-0129. - DOI - PMC - PubMed
    1. Go A. S., Mozaffarian D., Roger V. L., et al. Heart Disease and Stroke Statistics—2014 Update: a report from the American Heart Association. Circulation. 2014;129(3):e28–e292. doi: 10.1161/01.cir.0000441139.02102.80. - DOI - PMC - PubMed
    1. Ji S. T., Kim H., Yun J., Chung J. S., Kwon S. M. Promising therapeutic strategies for mesenchymal stem cell-based cardiovascular regeneration: from cell priming to tissue engineering. Stem Cells International. 2017;2017:13. doi: 10.1155/2017/3945403.3945403 - DOI - PMC - PubMed
    1. Vizoso F., Eiro N., Cid S., Schneider J., Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. International Journal of Molecular Sciences. 2017;18(9):p. 1852. doi: 10.3390/ijms18091852. - DOI - PMC - PubMed

LinkOut - more resources